Endothelial microparticle levels were higher in diabetic patients with macroangiopathy than in those with microangiopathy or no complications, and were independently associated with macroangiopathy.
Observational (n=149)
Do endothelial microparticle profiles differentiate the risk of macrovascular versus microvascular complications in patients with type 2 diabetes mellitus?
Endothelial microparticle profiles, specifically CD31+/CD42b- and CD31+/AV+ levels, may serve as useful biomarkers to differentiate the risk of macrovascular complications in patients with type 2 diabetes.
BACKGROUND: While the adverse impact of diabetes on microvessels is well known, the risks of macroangiopathy are less well recognized. Here, we determine the differential risk and endothelial microparticle (EMP) profile of vascular complications in type 2 diabetes mellitus. METHODS: Macroangiopathy was evaluated for cerebrovascular disease, coronary artery disease and peripheral artery disease; microangiopathy was evaluated for retinopathy, nephropathy and peripheral neuropathy. Clinical and laboratory factors were compared among 149 patients with no vascular complications or with microangiopathic and/or macroangiopathic complications. EMPs were also examined by flow cytometry using CD31, CD42b, annexin V (AV), and CD62E antibodies in the peripheral blood of patients. RESULTS: Diabetes of long duration, an elevated hemoglobin A1c (HbA1c) and concomitant hypertension were significantly associated with the occurrence of vascular complications. Dyslipidemia and a high body mass index were significantly associated with macroangiopathy, while diabetes of long duration and a high concentration of HbA1c were associated with microangiopathy. The EMP (CD31+/CD42b-, CD31+/AV+) levels were higher in patients with macroangiopathy than in patients with microangiopathy and no complications. The EMP level was also independently associated with macroangiopathy in diabetic patients. CONCLUSIONS: Microangiopathy and macroangiopathy in diabetic patients appear to have a different pathophysiological basis. The measurement of EMP would be helpful to differentiate the risk of diabetic vascular complications.
Jung et al. (Sat,) conducted a observational in Type 2 diabetes mellitus (n=149). Endothelial microparticle (EMP) levels vs. Patients with microangiopathy or no complications was evaluated on Association of EMP levels with macroangiopathy. Endothelial microparticle levels were higher in diabetic patients with macroangiopathy than in those with microangiopathy or no complications, and were independently associated with macroangiopathy.